The Latest Analyst Ratings for Unity Biotechnology
Portfolio Pulse from Benzinga Insights
In the last quarter, Unity Biotechnology (NASDAQ:UBX) received 3 bullish, 1 somewhat bullish, and 1 indifferent analyst ratings. The average 12-month price target for the company is $6.2, with a high of $10.00 and a low of $2.00. The average price target has increased by 43.19% over the past month.
June 26, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unity Biotechnology (NASDAQ:UBX) has received mostly positive analyst ratings in the last quarter, with an average 12-month price target of $6.2, which has increased by 43.19% over the past month.
The majority of analyst ratings for Unity Biotechnology are bullish or somewhat bullish, indicating a positive outlook for the stock. The average 12-month price target has also increased significantly over the past month, suggesting that analysts are becoming more optimistic about the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100